Showing results (251-260 of 678) with videos related to
Sort By:
Pageof 68
British Journal of Haematology|May 15, 2009
Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaAlison J Moskowitz, Miguel-Angel Perales, Tarun Kewalramani, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-IIOwen O'Connor, John Wright, Craig H Moskowitz, et al.Blood|August 11, 2005
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCLCraig H Moskowitz, Andrew D Zelenetz, Tarun Kewalramani, et al.Blood|May 12, 2017
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphomaPier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, et al.The Journal of Experimental Medicine|October 1, 1996
Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responsesD R Brown, D J Fowell, D B Corry, et al.Bone Marrow Transplantation|January 14, 2009
The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphomaB S Hoppe, C H Moskowitz, Z Zhang, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2007
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphomaC H Moskowitz, P A Hamlin, J Gabrilove, et al.Leukemia & Lymphoma|September 7, 2000
Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapyG B Donnelly, J Glassman, C Long, et al.Leukemia & Lymphoma|July 11, 2012
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphomaAndres Forero-Torres, Nancy Bartlett, Anne Beaven, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2016
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide ConditioningMichael Scordo, Valkal Bhatt, Meier Hsu, et al.Pageof 68